NcXHF

GEORGE J. BOSL
polycomb repressive complexes and stem cell microRNAs. Stem Cells
Dev. 2009;18:1093-1108.
46. Kushwaha R, Jagadish N, Kustagi M, et al. Interrogation of a contextspecifıc
transcription factor network identifıes novel regulators of pluripotency.
Stem Cells. 2015;33:367-377.
47. Pallesen G, Hamilton-Dutoit SJ. Ki-1 (CD30) antigen is regularly expressed
by tumor cells of embryonal carcinoma. Am J Pathol. 1988;133:
446-450.
48. Santagata S, Ligon KL, Hornick JL. Embryonic stem cell transcription
factor signatures in the diagnosis of primary and metastatic germ cell
tumors. Am J Surg Pathol. 2007;31:836-845.
49. Gopalan A, Dhall D, Olgac S, et al. Testicular mixed germ cell tumors: a
morphological and immunohistochemical study using stem cell markers,
OCT3/4, SOX2 and GDF3, with emphasis on morphologically
diffıcult-to-classify areas. Mod Pathol. 2009;22:1066-1074.
50. Korkola JE, Houldsworth J, Bosl GJ, et al. Molecular events in germ cell
tumours: linking chromosome-12 gain, acquisition of pluripotency and
response to cisplatin. BJU Int. 2009;104:1334-1338.
51. Korkola JE, Houldsworth J, Feldman DR, et al. Identifıcation and validation
of a gene expression signature that predicts outcome in adult
men with germ cell tumors. J Clin Oncol. 2009;27:5240-5247.
52. Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant
transformation: diverse malignant histologies arising in men with germ
cell tumors. J Urol. 1998;159:133-138.
53. Ulbright TM, Hattab EM, Zhang S, et al. Primitive neuroectodermal
tumors in patients with testicular germ cell tumors usually resemble
pediatric-type central nervous system embryonal neoplasms and lack
chromosome 22 rearrangements. Modern Pathology. 2010;23:972-980.
54. Honecker F, Wermann H, Mayer F, et al. Microsatellite instability, mismatch
repair defıciency, and BRAF mutation in treatment-resistant
germ cell tumors. J Clin Oncol. 2009;27:2129-2136.
55. Feldman DR, Iyer G, Van Alstine L, et al. Presence of somatic mutations
within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatinresistant
germ cell tumors. Clin Cancer Res. 2014;20:3712-3720.
56. Rao PH, Houldsworth J, Palanisamy N, et al. Chromosomal amplifıcation
is associated with cisplatin resistance of human male germ cell tumors.
Cancer Res. 1998;58:4260-4263.
57. Houldsworth J, Xiao H, Murty VV, et al. Human male germ cell tumor
resistance to cisplatin is linked to TP53 gene mutation. Oncogene. 1998;
16:2345-2349.
58. Einhorn LH, Brames MJ, Heinrich MC, et al. Phase II study of imatinib
mesylate in chemotherapy refractory germ cell tumors expressing KIT.
Am J Clin Oncol. 2006;29:12-13.
59. Albany C, Feldman D, Garbo L, et al. Antitumor activity of brentuximab
vedotin in CD30 positive refractory germ cell tumors. J Clin Oncol.
2013;31:6s (suppl; abstr 327).
60. Feldman DR, Turkula S, Ginsberg MS, et al. Phase II trial of sunitinib in
patients with relapsed or refractory germ cell tumors. Invest New Drugs.
2010;28:523-528.
61. Feldman DR, Einhorn LH, Quinn DI, et al. A phase II multicenter evaluation
of ARQ 197 monotherapy in patients with relapsed or refractory
germ cell tumors (GCTs). J Clin Oncol. 2011;29:15s (suppl; abstr 4638).
62. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Longterm
cause-specifıc mortality of patients treated for Hodgkin’s disease.
J Clin Oncol. 2003;21:3431-3439.
63. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity
after treatment for Hodgkin lymphoma. Blood. 2007;109:
1878-1886.
64. Schilsky RL. Renal and metabolic toxicities of cancer chemotherapy. Semin
Oncol. 1982;9:75-83.
65. Bajorin DF. The graying of testis cancer patients: what have we learned?
J Clin Oncol. 2007;25:4341-4343.
e258
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook